Navigation Links
Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference
Date:11/30/2011

CRANBURY, N.J., Nov. 30, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that Dr. Carl Spana, President and Chief Executive Officer, will be presenting at Windhover's Therapeutic Area Partnerships conference on Thursday, December 1, 2011.  The conference will be held at the Westin Copley Place in Boston, MA.  Dr. Spana will be presenting an overview on Palatin's Phase 2b trial for bremelanotide in premenopausal women with female sexual dysfunction, and the Phase 1 trial for AZD2820, under development for the treatment of obesity, in collaboration with AstraZeneca.  Bremelanotide, the Company's lead drug candidate, was named one of the "2011 Top Projects to Watch" by Windhover.

ABOUT THE CONFERENCE

Windhover's Therapeutic Area Partnerships conference is a uniquely focused meeting among R&D, financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking. For more information on the conference and presenting companies please go to http://www.tapartnerships.com.  

ABOUT PALATIN TECHNOLOGIES, INC.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.


 

 


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at 10th Annual BIO Investor Forum
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
5. Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
6. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
8. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
9. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
10. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
11. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2018)... Columbia (PRWEB) , ... August 17, 2018 , ... ... International Society for Biological and Environmental Repositories (ISBER) is pleased to announce the ... , The Fourth Edition publication, originally released in January 2018, is a practice-changing ...
(Date:8/11/2018)... N.J. (PRWEB) , ... August 10, 2018 , ... Researchers ... fracturing while under pressure. The Explosion Protection Chamber for High-Pressure NMR & EPR ... new level of safety to the laboratory. , High-pressure experiments have significantly grown ...
(Date:8/9/2018)... ... August 08, 2018 , ... Since their establishment in 2012, ... with a team nearly double its’ size from last year, the company is thrilled ... turned heads and impressed crowds at a private product launch event during the ...
(Date:8/7/2018)... BOSTON (PRWEB) , ... August 06, 2018 , ... ... life sciences and diagnostics companies, announces the placement of Dr. Paul Harney as ... delivering Prescient’s North America growth strategy and enhancing client satisfaction. He was also ...
Breaking Biology Technology:
(Date:8/1/2018)... ... August 01, 2018 , ... Dr. Asher Kimchi, Founder and Chairman ... of the 2018 IAC Awards at the 23rd World Congress on Heart Disease held ... four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with ...
(Date:7/31/2018)... ... , ... ACEA Biosciences, is a privately owned biotechnology company which develops cutting ... RTCA S16, which the ideal entry level model for exploratory studies in cell biology. ... in any standard CO2 tissue culture incubator. The user friendly RTCA software allows ...
(Date:7/29/2018)... ... July 29, 2018 , ... Dr. William Plikerd, an evidence-based ... nutraceutical to improve overall immunity and to combat inflammation and autoimmune disorders. , ... The following data was reported:, Up to 260% increase ...
Breaking Biology News(10 mins):